Nagata M, Tabe K, Houya I, Kiuchi H, Sakamoto Y, Yamamoto K, Dohi Y
Second Department of Internal Medicine, Saitama Medical School.
Nihon Kyobu Shikkan Gakkai Zasshi. 1991 Apr;29(4):413-9.
In order to clarify whether repirinast, an inhibitor of chemical mediator release, could influence the pharmacokinetics of theophylline, a loading test using intravenous injection of aminophylline was performed in 10 subjects with bronchial asthma before and after treatment with 300 mg/day of repirinast. There was no significant difference in theophylline half-life before treatment (7.25 +/- 2.43 hr) and after treatment (7.82 +/- 3.35 hr). There was no significant difference in theophylline clearance before treatment (0.047 +/- 0.018 L/kg/hr) and after treatment (0.047 +/- 0.020 L/kg/hr). These results demonstrated that repirinast does not modify theophylline pharmacokinetics significantly.
为了阐明化学介质释放抑制剂瑞吡司特是否会影响茶碱的药代动力学，对10名支气管哮喘患者在每日服用300 mg瑞吡司特治疗前后进行了静脉注射氨茶碱的负荷试验。治疗前茶碱半衰期（7.25±2.43小时）与治疗后（7.82±3.35小时）无显著差异。治疗前茶碱清除率（0.047±0.018 L/kg/小时）与治疗后（0.047±0.020 L/kg/小时）无显著差异。这些结果表明，瑞吡司特不会显著改变茶碱的药代动力学。
